Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Beth Chasen et al.|New England Journal of Medicine|2017Cited by 3.2k
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factorsLisa Bodei, Irvin M. Modlin, Mark Kidd et al.|European Journal of Nuclear Medicine and Molecular Imaging|2014Cited by 465
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward M. Wolin, Beth Chasen et al.|Journal of Clinical Oncology|2018Cited by 388